A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
Micromet’s tech has yielded two marketed drugs, one still in the clinic... and 14 discontinuations.
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.